Australasian Leukaemia & Lymphoma Group (ALLG)’s Post

Treating Burkitt’s leukemia and lymphoma involves a range of approaches tailored to the individual’s condition. Common treatment options include: Chemotherapy: Using powerful drugs to kill cancer cells and reduce tumors. Targeted Therapy: Utilizing medications that specifically target cancer cells while sparing healthy ones. Immunotherapy: Boosting the body’s immune system to fight cancer more effectively. Radiation Therapy: Applying targeted radiation to destroy cancer cells in specific areas. Stem Cell Transplant: Replacing damaged bone marrow with healthy stem cells to restore normal blood cell production. Choosing the right treatment depends on the specific characteristics of the cancer and the patient’s overall health. Consulting with a healthcare provider is essential for developing a personalized treatment plan. #BurkittsLeukemia #BurkittsLymphoma #CancerTreatment #Hematology #Chemotherapy #TargetedTherapy #Immunotherapy #RadiationTherapy #StemCellTransplant #CancerCare #Oncology #HealthEducation #PatientCare

In another milestone since the implementation of CAR-T therapy at Jiahui, the first myeloma patient treated with CAR-T at Jiahui International Hospital was recently discharged two weeks after infusion. The foreign patient was first diagnosed with multiple myeloma in 2008. Despite multiple treatments including chemotherapy, immunotherapy, target treatment, and two autologous stem cell transplantations, he relapsed with extramedullary metastasis which caused multiple bone destruction in 2022. Due to the highly aggressive nature of extramedullary multiple myeloma, previous exposure to more than five lines of treatments, and a possible short remission time, there was a risk of a poor prognosis. This meant that the patient required more effective treatment. Based on current clinical data, the recent emergence of CAR-T therapy provides the best option for high-risk and relapsed multiple myeloma. The patient expressed his gratitude for his experience at Jiahui, noting that “my entire treatment journey at Jiahui has been smooth throughout. I’ve had really good support from the medical team – from my doctors through to the nursing team. It’s been a good experience”. He went on to note that “while every patient is different, my side effects were ok and I know Jiahui’s team watched me really closely, so it's been a real bonus during the last few weeks.” Click here to read the full story: https://lnkd.in/dXGKrJ7w Click here to learn more about Jiahui International Cancer Center: https://lnkd.in/gixHXSP5 #JiahuiHealth #CARTtherapy #cancertreatment #multiplemyeloma #medicalinnovation #immunotherapy #patientstory #cancer #celltherapy

Do you know that Multiple Myeloma is a cancer that begins in plasma cells? Plasma is a type of white blood cell in your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones. Common symptoms may include bone pain, often in the back or ribs, fractures, weakness, weight loss and frequent urination. Your treatment depends on how advanced the disease is: you may not need treatment right away or you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Have you been diagnosed with Multiple Myeloma? Join our Blood Cancer Support Group on the 4th Monday of the month at 6:00pm via Zoom. Register to join us at https://lnkd.in/d87jWAC2 #CSCDE #cancersupport #cancerawareness #mentalhealthawareness #cancersurvivor #cancercommunity #supportforcancer #multiplemyelomaawareness

Would you like to know how exactly we support patients with #lymphoma and #leukaemia? The clue is the 𝗪𝗣𝗖 𝗰𝗵𝗮𝗻𝗻𝗲𝗹! 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗻𝗴 𝘀𝘂𝘀𝗽𝗲𝗰𝘁𝗲𝗱 𝗺𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝘁 𝗰𝗲𝗹𝗹𝘀: Combining the WPC channel with our WDF channel inside a single analyser allows us to detect suspected malignant cells sensitively and specifically. 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗶𝗻 𝗻𝗲𝗲𝗱 𝗼𝗳 𝘀𝘁𝗲𝗺 𝗰𝗲𝗹𝗹 𝘁𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝗮𝘁𝗶𝗼𝗻: The WPC channel can also be used to quantify haematopoietic progenitor cells. This is a fast method to monitor stem cell mobilisation and determine the optimal time point to start apheresis. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲! Dive deeper into the principles behind the Sysmex WPC channel and its reagents in our White paper. 👀 https://lnkd.in/ey2DHKuJ 📢 𝗦𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱 to explore how Sysmex Europe Flow Cytometry can support blood cancer diagnostics! #BloodCancerAwarenessMonth

Would you like to know how exactly we support patients with #lymphoma and #leukaemia? The clue is the 𝗪𝗣𝗖 𝗰𝗵𝗮𝗻𝗻𝗲𝗹! 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗻𝗴 𝘀𝘂𝘀𝗽𝗲𝗰𝘁𝗲𝗱 𝗺𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝘁 𝗰𝗲𝗹𝗹𝘀: Combining the WPC channel with our WDF channel inside a single analyser allows us to detect suspected malignant cells sensitively and specifically. 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗶𝗻 𝗻𝗲𝗲𝗱 𝗼𝗳 𝘀𝘁𝗲𝗺 𝗰𝗲𝗹𝗹 𝘁𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝗮𝘁𝗶𝗼𝗻: The WPC channel can also be used to quantify haematopoietic progenitor cells. This is a fast method to monitor stem cell mobilisation and determine the optimal time point to start apheresis. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲! Dive deeper into the principles behind the Sysmex WPC channel and its reagents in our White paper. 👀 https://lnkd.in/ey2DHKuJ 📢 𝗦𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱 to explore how Sysmex Europe Flow Cytometry can support blood cancer diagnostics! #BloodCancerAwarenessMonth

Glad to share this certificate of completion Recently I had completed a CME course titled : "Updates in Chronic Lymphocytic Leukemia" offered by Leukemia and Lymphoma Society National Cancer Institute (NCI) World Health Organization These courses cover the following objectives : Describe the types and subtypes of chronic lymphocytic leukemia (CLL) Identify tests used to diagnose disease and monitor treatment Explain approved and emerging treatment options for CLL Describe strategies to manage treatment side effects as well as long-term and late effects of treatments Review vaccination strategies, the impact of COVID-19, and importance of screening for secondary cancers Describe the role of the multidisciplinary healthcare team in managing patients with CLL #cancer #lymphoma #oncology #pharmacotherepy #pathophysiology #anatomy #physiology #biochemistry #clinicaldiagnosis #clinicalpharmacy #pharmacyresident #medicalstudent #medicalscience #pharmacology #hospital #emergencymedicine

🌷**High Risk Multiple Myeloma Solution and Chinese Expert Consensus**🌷 High risk multiple myeloma (HRMM) refers to patients with multiple myeloma whose overall survival is less than 2 to 3 years under current standard treatments. In 2024, the Chinese Society of Clinical Oncology's Multiple Myeloma Expert Committee and the Chinese Anti-Cancer Association's Hematologic Oncology Committee, organized by relevant experts, developed the "Chinese Expert Consensus on the Diagnosis and Treatment of High Risk Multiple Myeloma (2024 Edition)," which was officially published in the *Chinese Journal of Hematology* in May 2024. This consensus defines HRMM, outlines high-risk factors and risk stratification systems, and provides key treatment recommendations for HRMM, aiming to improve the quality of life and prognosis for HRMM patients in China. 🌸**Definition of HRMM**🌸 There is currently no precise definition of HRMM. Referencing the International Myeloma Working Group (IMWG)'s definition, the Chinese Expert Committee considers HRMM patients as those with an overall survival (OS) of less than 3 years after receiving autologous hematopoietic stem cell transplantation (auto-HSCT) or less than 2 years if they have not received auto-HSCT. Patients with OS of less than 2 years after receiving auto-HSCT are classified as ultra-high risk multiple myeloma (UHRMM) patients. More info clic→ https://lnkd.in/gY3UYKgB 🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine In China for preliminary evaluation! WhatsApp: +8613717959070 Email: doctor.huang@globecancer.com #HighRiskMultipleMyeloma #HRMM #MultipleMyeloma #CancerTreatment #Hematology #Oncology #MedicalResearch #CancerCare #CancerAwareness #ChinaMedicalAdvances #AutoHSCT #MedicalConsensus #UHRMM #BloodCancer

Post-allo-HSCT outcomes for #AML show: ▪️3-year relapse rate changed from 37%-31% and then to 30% from 2000-2021 ▪️3 year leukemia-free survival increased from 32%, 38% and, 44% ▪️OS increased from 37%, 42%, and 49% https://lnkd.in/ekejs_5d #leusm #cancer #oncology

Combining CRISPR-Cas9 with immunotherapy is an exciting frontier in cancer treatment. By editing immune cells, researchers are enhancing their ability to attack tumors. #CRISPRCas9 #Immunotherapy #CancerResearch References: Deuse, T., et al. (2019). The SIRPα–CD47 immune checkpoint in xenogeneic hematopoietic stem cell transplantation. Nature Communications, 10(1), 3345. Zhang, C., et al. (2017). CRISPR-Cas9-mediated PD-1 disruption enhances anti-tumor activity of human T cells. Scientific Reports, 7(1), 1505. doi:10.1038/s41598-017-01532-5 Ren, J., et al. (2017). A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget, 8(10), 17002-17011. doi:10.18632/oncotarget.15218

#nuclear_medicine case Case presentation: A 34 y/o male patient with history of abdominal distention and discomfort and biopsy proven #Burkitt #lymphoma was referred for staging with F-18 #FDG #PET_CT The scan (lower part of the image) showed widespread hypermetabolic supra and infradiaphragmatic areas including diffuse peritoneal lining (peritoneal lymphmatosis), bone marrow involvement as well as multiple hypermetabolic lymph nodes. Physiological activity in the brain, liver, spleen and kidneys decreased considerably (#superscan). Post #chemotherapy scan following R-CHOP showed complete metabolic response to treatment (top images). Take home notes: 1- Peritoneal lymphomatosis can occur in diffuse large B-cell lymphoma (#DLBCL ) and Burkitt lymphoma. This entity has intense hypermetabolism on F-18 FDG PET/CT 2- F-18 FDG PET/CT superscan pattern with decreased physiological uptake (note minimal brain activity on staging phase and normal brain activity on post-chemo phase) can occur in patients with high burden of hypermetabolic tumors. 3- Burkitt lymphoma is a high grade lymphoma with proven F-18 FDG avidity. However due to its fulminant onset and progression as well as dramatic response to treatment, usually staging and response evaluation do not include PET imaging. Our case shows the feasibility of F-18 FDG PET/CT in this clinical setting #oncology #Lymphoma